Abstract 420P
Background
Cytoreductive surgery (CRS) is a major surgery which consist of extensive tumor debulking, peritonectomy, and multiple visceral resections. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a technique in which chemotherapy is delivered in a heated solution perfused throughout the peritoneal space. In centers performing CRS-HIPEC, a significant survival benefit were observed; However, the rate of post-operative complications remains high. Acute kidney injury is a post-operative complication associated with increased morbidity and mortality and may cause delay in adjuvant chemotherapy or worse, may render the patient ineligible to receive systemic chemotherapy.
Methods
This was a retrospective cohort study, data were collected among adult patients with peritoneal carcinomatosis from colorectal, appendiceal, gastric, gynecologic cancers, and primary peritoneal mesothelioma who underwent CRS-HIPEC between Jan. 2012 and Dec. 2021 at St. Luke’s Medical Center. Data were obtained retrospectively through review of electronic medical records.
Results
A total of 162 patients who met the inclusion criteria were included in the study. Most of the patients were above 60 years old (62; 38%), females (134; 83%), had normal BMI (90; 56%), with ECOG PS 1 (160; 99%) and without comorbidities (84; 52%). Most had gynecologic malignancy (101; 63%) with high tumor grade (92; 58%) and were given with intraperitoneal cisplatin (16l 68%). Elderly patients (OR 2.70 [95% CI 0.88-8.29]; p .043 < .05); with comorbidities (OR 6.52 [95% CI 3.2-13.2]; p .001 < .05); and was given intraperitoneal Cisplatin (OR 3.99 [95% CI 1.99-8.03]; p .001 < 05) were all found to be at a higher risk for developing AKI after CRS-HIPEC.
Conclusions
The investigation noted that the elderly patients with comorbidities were found to have the highest risk of developing post-operative AKI. The most common malignancy was gynecologic cancers with high tumor grade. Cisplatin was the most common intraperitoneal chemotherapy administered and was associated with higher risk of developing acute kidney injury compared to other chemotherapy agents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
430P - Single-cell spatial architecture of tumour microenvironment in patients with in-transit melanoma (ITM)
Presenter: Camelia Quek
Session: Poster viewing 06
431P - Alveolar soft part sarcomas: A tertiary care Indian centre experience
Presenter: Jyoti Bajpai
Session: Poster viewing 06
432P - Representation of countries and gender in abstracts at the 2022 American Society of Clinical Oncology Annual Scientific Meeting (ASCO ASM)
Presenter: Laure-Anne Teuwen
Session: Poster viewing 06
433P - Variations in radiation oncology treatment access in Asia and its implications on cancer care
Presenter: Abhishek Krishna
Session: Poster viewing 06
434P - Outcome of high grade glioma patients: A single institution experience
Presenter: Adeeba Zaki
Session: Poster viewing 06
435P - The pattern of presentation of cancer in young adults from a tertiary care centre: A cause for concern
Presenter: Deepa Joseph
Session: Poster viewing 06
436P - Oncologic outcomes in patients with extraskeletal Ewing’s sarcoma (EES): A tertiary care centre experience
Presenter: Ashish Gulia
Session: Poster viewing 06
437P - The prevalence of burnout among medical oncology fellows-in-training in the Philippines: A cross-sectional study
Presenter: Daphne Lee
Session: Poster viewing 06
438P - Estimating scenarios for survival time in patients with metastatic melanoma receiving immunotherapy or targeted therapy
Presenter: Megan Smith-Uffen
Session: Poster viewing 06
439P - Evaluating Ewing’s sarcoma as the prototype for cancer care in teenage and young adults (TYA): A single-center retrospective cross-sectional study
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06